Genebiotech logo. /Courtesy of Genebiotech

According to the Financial Supervisory Service's electronic disclosure system (Dart) on the 27th, Kim Sung-ho, CEO of Renumedical, disclosed that he bought 89,235 shares of Genebiotech, a KOSDAQ-listed company, in the market. The amount is approximately 400 million won. CEO Kim's equity stake has increased from the previous 7.79% to 8.83%.

CEO Kim, who is active as a ‘big player’ individual investor in the domestic stock market, has been intensively purchasing equity in Genebiotech since last month. He is now the second-largest shareholder after Lee Chan-ho, the CEO of Genebiotech, who holds 28.09%.

CEO Kim disclosed that the purpose of this equity purchase is simply for investment. However, according to industry sources, it is also known that there is a possibility of management participation through additional equity acquisition in the future.